Evidence map›Paper›PMID 29527914›Full record

ArticlePhysiological research2018

Effect of angiotensin-converting enzyme blockade, alone or combined with blockade of soluble epoxide hydrolase, on the course of congestive heart failure and occurrence of renal dysfunction in Ren-2 transgenic hypertensive rats with aorto-caval fistula.

P Kala, L Sedláková, P Škaroupková, L Kopkan, Z Vaňourková, M Táborský, A Nishiyama, S H Hwang, B D Hammock, J Sadowski and 3 more

Open access · goldAbstract read
In one paragraph

Article in Physiological research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. ATScientific reports · 2021
    Article
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 4 countries.

P KalaCenter for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague 4, Czech Republic. luce@medicon.cz.
L Sedláková
P Škaroupková
L Kopkan
Z Vaňourková
M Táborský
A Nishiyama
S H Hwang
B D Hammock
J Sadowski
V Melenovský
J D Imig
L Červenka
Institute of Clinical and Experimental Medicine · CZUniversity of California, Davis · USCharles University · CZKagawa University · JPMedical College of Wisconsin · USMossakowski Medical Research Institute, Polish Academy of Sciences · PLUniversity Hospital Olomouc · CZ

Funding

Eicosanoid-based Therapy for DiabetesR01DK103616 · NIDDK · MEDICAL COLLEGE OF WISCONSIN · PI IMIG, JOHN D · 2015 to 2019
$2.4M
NIDDK NIH HHS R01 DK103616
6 · The paper itself

Abstract

We showed recently that increasing kidney epoxyeicosatrienoic acids (EETs) by blocking soluble epoxide hydrolase (sEH), an enzyme responsible for EETs degradation, retarded the development of renal dysfunction and progression of aorto-caval fistula(ACF)-induced congestive heart failure (CHF) in Ren-2 transgenic hypertensive rats (TGR). In that study the final survival rate of untreated ACF TGR was only 14 % but increased to 41 % after sEH blockade. Here we examined if sEH inhibition added to renin-angiotensin system (RAS) blockade would further enhance protection against ACF-induced CHF in TGR. The treatment regimens were started one week after ACF creation and the follow-up period was 50 weeks. RAS was blocked using angiotensin-converting enzyme inhibitor (ACEi, trandolapril, 6 mg/l) and sEH with an sEH inhibitor (sEHi, c-AUCB, 3 mg/l). Renal hemodynamics and excretory function were determined two weeks post-ACF, just before the onset of decompensated phase of CHF. 29 weeks post-ACF no untreated animal survived. ACEi treatment greatly improved the survival rate, to 84 % at the end of study. Surprisingly, combined treatment with ACEi and sEHi worsened the rate (53 %). Untreated ACF TGR exhibited marked impairment of renal function and the treatment with ACEi alone or combined with sEH inhibition did not prevent it. In conclusion, addition of sEHi to ACEi treatment does not provide better protection against CHF progression and does not increase the survival rate in ACF TGR: indeed, the rate decreases significantly. Thus, combined treatment with sEHi and ACEi is not a promising approach to further attenuate renal dysfunction and retard progression of CHF.

Indexed as

Angiotensin-Converting Enzyme InhibitorsAnimalsArteriovenous FistulaBenzoatesDrug Evaluation, PreclinicalDrug Therapy, CombinationEpoxide HydrolasesFemaleHeart FailureIndolesMaleRatsRats, Sprague-DawleyRats, TransgenicRenal InsufficiencyUrea4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acidAngiotensin-Converting Enzyme InhibitorsBenzoatesEpoxide HydrolasesIndolestrandolaprilUrea

Identifiers

PMID29527914
PMCPMC6056335
OpenAlexW3022431223

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.